CN1110560A - "Zhibituo" drug - Google Patents
"Zhibituo" drug Download PDFInfo
- Publication number
- CN1110560A CN1110560A CN 95111224 CN95111224A CN1110560A CN 1110560 A CN1110560 A CN 1110560A CN 95111224 CN95111224 CN 95111224 CN 95111224 A CN95111224 A CN 95111224A CN 1110560 A CN1110560 A CN 1110560A
- Authority
- CN
- China
- Prior art keywords
- zhibituo
- weight
- drug
- powder
- adjuvant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The medicine in the form of tablet, capsule, powder, or instant granules for curing hyperlipemia with advantages of high curative effect and no poison contains monascin powder (50-100 Wt.%) and auxiliary materials (0-50 wt.%).
Description
The present invention relates to a kind of medicine, particularly relate to a kind of " Zhibituo " drug that is used for the treatment of hyperlipemia.
Later men and women all had hyperlipemia in various degree in 45 years old, and sickness rate is high, and hyperlipemia is the principal element that causes coronary heart disease, so hyperlipemia is prevented and treatment is very important.At present domestic mainly based on imported medicine, as MEVACOR Teroltrat (the Lovastatin Lip river is for its fourth MSD).Price is expensive, and side effect is big.And the uncertain therapeutic efficacy of domestic clinical first-selected Chinese medicine preparation inositol niacinate is cut.
The object of the present invention is to provide the pure natural fat-reducing medicament " Zhibituo " drug of a kind of determined curative effect, safety non-toxic.
The component of " Zhibituo " drug of the present invention comprises Hongqu powder (red colouring agent) 50～100%(weight), adjuvant 0～50%(weight).Wherein Monas cuspurpureus Went is that Aspergillaceae fungus monascus parpureus Went Monasc us parpureus Went is inoculated on the rice, forms through fermentation.Via is made of rice and monascorubin.The chemical composition of rice is starch (more than 70%), protein (7-16%), vitamin (being mainly vitamin B group 2-3%), inorganic salt (1.5～3%).The chemical composition of monascorubin is red pigments (more than 80%), xanthein and purple pigment.Red pigments is made up of Pan Hong (142～143 ℃ of fusing points) and dream rubine (fusing point 156-157 ℃).Xanthein is formed with ankaflavin by dream is red.Purple pigment is made up of Pan Hong amine and dream rubine amine.The structural formula of above-mentioned substance is as follows respectively:
Red pigments:
Xanthein:
Purple pigment:
" Zhibituo " drug of the present invention can be tablet, capsule, powder and electuary.The component of zhibituo tablet is a Hongqu powder (red colouring agent) 60-85%(weight), adjuvant 15-40%(weight).The ratio that each adjuvant accounts for total amount is binding agent 0.5～5%(weight), lubricant 1-15%(weight), disintegrating agent 0-13%(weight), plasticizer 0-10%(weight) coating material 0-2%(weight).Wherein binding agent is sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, starch slurry, dextrin etc.Lubricant is magnesium stearate, Pulvis Talci, liquid Paraffin etc.Disintegrating agent is starch and derivant, cellulose family etc.Plasticizer is ethylene glycol, glycerol, Polyethylene Glycol etc.Coating material is the sugar-coat dress material, thin film dress material, enteric coat etc.; The capsular adjuvant of zhibituo is a filler, as starch, dextrin etc., is generally the 0-50%(weight of total amount); The adjuvant of zhibituo powder is filler and sugar, as starch, dextrin, lactose etc., is generally the 0-50%(weight of total amount); The adjuvant of zhibituo electuary is filler and sugar, as starch, dextrin etc.
The acute toxicity test of " Zhibituo " drug of the present invention shows that one day administration 24000mg/kg(of animal (ICR mice) is equivalent to 400 times of clinical dosages) observe week nothing death continuously, there is not significantly other toxic reaction, animal is in order.After the execution, pathological anatomy is observed, no abnormal organic disease, and the mice maximum tolerated dose of " Zhibituo " drug is 24000mg/kg.
The long-term toxicity test for animals of " Zhibituo " drug of the present invention (15 of the above Canis familiaris L.s of body weight 8kg are divided three groups, the I group be zhibituo high dose group, every day gastric infusion 100mg/ml liquid 3000mg/kg, be equivalent to 50 times of clinical dosages; The II group is the zhibituo low dose group, and every day, gastric infusion 150mg/ml liquid 600mg/kg was equivalent to 10 times of clinical dosages; The III group is the blank group, irritates stomach and gives the normal saline of equivalent.) result shows, zhibituo successive administration three months, to the weight of animals, food-intake, behavior, gait, spirit, activity, call reaction, routine urinalysis, hematology, blood biochemical are learned, each organ pipe is organized does not all have influence, and " Zhibituo " drug is a kind of safe preparation.
" Zhibituo " drug treatment hyperlipemia clinical test results of the present invention shows that total obvious effective rate is 73.00%, and total effective rate is 88.00%, compares with the control drug inositol niacinate, and curative effect obviously is better than control drug, and is as shown in table 1.Clinical trial shows that also " Zhibituo " drug has the effect of definite cholesterol reducing (TC), triglyceride (TG) and TC-HDL-C/HDL-C value, and the effect of good high density lipoprotein increasing (HDL/C) is arranged.
" Zhibituo " drug of the present invention is evident in efficacy, and is rapid-action, and effect is lasting, taking convenience, the pure natural fat-reducing medicament of safety non-toxic, production technology are easy, and the prices of raw and semifnished materials are low, resource is very abundant, and its curative effect is better than inositol niacinate, and price is lower than import medicine Teroltrat and gemfibrozil.And do not have obvious toxic-side effects, and Teroltrat there are gastrointestinal reaction, liver response, tired, sleep disorder, dysgeusia, anaphylaxis, youngster are had side effect such as harm.Be mainly used in the treatment hyperlipemia.
Describe the embodiment of the invention below in detail.
Embodiment 1: the zhibituo tablet
Prescription:
Hongqu powder (red colouring agent) 100g
Carboxymethyl cellulose sodium 4g
Magnesium stearate 10g
Polyethylene Glycol-4000 6g
With Hongqu powder (red colouring agent), Polyethylene Glycol-4000 mix homogeneously, preparation sodium carboxymethyl cellulose binder solution is sprayed on the medicated powder, granulation, drying, granulate, adding magnesium stearate lubricant tabletting, and the making sheet packing gets the zhibituo tablet.
Embodiment 2: the zhibituo capsule
Prescription:
Hongqu powder (red colouring agent) 100g
Starch 20g
Above-mentioned component is mixed all, and drying is divided the capsule of packing into, making sheet, the zhibituo capsule.
Embodiment 3: zhibituo powder
Prescription:
Hongqu powder (red colouring agent) 100g
Starch 10g
With above-mentioned component mix homogeneously, drying is divided the bag of packing into, gets zhibituo powder.
Embodiment 4: zhibituo suspendible electuary
Prescription:
Hongqu powder (red colouring agent) 100g
Dextrin 10g
Sucrose 5g
With above-mentioned component mix homogeneously, to granulate, drying is divided the bag of packing into, gets zhibituo suspendible electuary.
Table 1: " Zhibituo " drug treatment hyperlipemia curative effect relatively
| Group | The example number | Curative effect | Obvious effective rate % | Efficient % | |||
| Produce effects | Effectively | Invalid | Worsen | ||||
| Treatment group | 100 | 73 | 15 | 10 | 2 | 73.00 | 88.00 |
| Control group (hexanicit) | 60 | 24 | 12 | 20 | 4 | 40.00 | 60.00 |
Claims (3)
1, a kind of " Zhibituo " drug that is used for the treatment of hyperlipemia is characterized in that component comprises Hongqu powder (red colouring agent) 50～100% (weight), adjuvant 0～50% (weight).
2, " Zhibituo " drug as claimed in claim 1, the component that it is characterized in that the zhibituo tablet is, Hongqu powder (red colouring agent) 60～85%(weight), adjuvant 15～40%(weight), wherein each adjuvant accounts for the ratio of gross weight and is, binding agent 0.5～5%(weight), lubricant 1～15%(weight), disintegrating agent 0～13%(weight), plasticizer 0～10%(weight), coating material 0～2%(weight).
3, " Zhibituo " drug as claimed in claim 1, the adjuvant that it is characterized in that zhibituo capsule, zhibituo powder and zhibituo electuary are filler or filler and sugar.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 95111224 CN1110560A (en) | 1995-01-24 | 1995-01-24 | "Zhibituo" drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 95111224 CN1110560A (en) | 1995-01-24 | 1995-01-24 | "Zhibituo" drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1110560A true CN1110560A (en) | 1995-10-25 |
Family
ID=5078534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 95111224 Pending CN1110560A (en) | 1995-01-24 | 1995-01-24 | "Zhibituo" drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1110560A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999023996A2 (en) * | 1997-11-06 | 1999-05-20 | Peking University | Compositions containing red rice fermentation products, frementation processes and monascus strains therefor |
| US7238348B2 (en) | 1996-09-30 | 2007-07-03 | Beijing Peking University Wbl Corporation Ltd. | Method of treatment of osteoporosis with compositions of red rice fermentation products |
| EP2559433A1 (en) * | 2011-08-17 | 2013-02-20 | Sunway Biotech Co., Ltd. | Composition for lowering blood lipid and elevating high-density lipoprotein and method for manufacturing the same |
-
1995
- 1995-01-24 CN CN 95111224 patent/CN1110560A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6632428B1 (en) | 1996-09-30 | 2003-10-14 | Peking University | Methods and compositions employing red rice fermentation products |
| US7238348B2 (en) | 1996-09-30 | 2007-07-03 | Beijing Peking University Wbl Corporation Ltd. | Method of treatment of osteoporosis with compositions of red rice fermentation products |
| WO1999023996A2 (en) * | 1997-11-06 | 1999-05-20 | Peking University | Compositions containing red rice fermentation products, frementation processes and monascus strains therefor |
| WO1999023996A3 (en) * | 1997-11-06 | 1999-08-19 | Univ Beijing | Compositions containing red rice fermentation products, frementation processes and monascus strains therefor |
| EP2559433A1 (en) * | 2011-08-17 | 2013-02-20 | Sunway Biotech Co., Ltd. | Composition for lowering blood lipid and elevating high-density lipoprotein and method for manufacturing the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20070253980A1 (en) | New pharmaceutical composition from natural materials for regulating immunity, its preparation method and use | |
| CN101756990B (en) | Medical composition for losing weight or treating hyperlipidemia | |
| CN1110560A (en) | "Zhibituo" drug | |
| CN1092986C (en) | CoA oral preparation for reducing blood fat and its preparation method | |
| CN102100751A (en) | Preparation technology of new integrative formulation of largetrifoliolious bugbane rhizome and kudzuvine root decoction and production method thereof | |
| US20030109490A1 (en) | Composite stimulating iNOS enzyme which induce immuno-reactant nitric oxide synthesis and process for preparing the same | |
| CN1969895A (en) | Enteric-coated formulation of creat and preparation process thereof | |
| CN101313928A (en) | Southernwood oil and medicine uses of its preparations | |
| CN1389475A (en) | Wolfberry polysaccharide and its prepn. and application | |
| CN103113359B (en) | Silybin bis-bias succinate and pharmaceutical salts thereof | |
| CN103768454B (en) | A kind of composition with prevention and treatment HIV/AIDS and preparation method thereof | |
| US3876778A (en) | Use of antibiotics of the streptothricin family as taeniacidal agents | |
| CN103271907B (en) | Oral medicine composition consisting of berberine and melbine, and preparation method thereof | |
| CN101062040B (en) | Stable type cucurbitacin liquid formula and the agent thereof | |
| CN1125106A (en) | Chang'an capsule and its preparation method and application | |
| CN103193768B (en) | The silybin bis-bias succinate isomer for the treatment of hepatopathy | |
| AU2020104012A4 (en) | Traditional Chinese Medicine Composition for Treating/Preventing Diabetes and Application Thereof | |
| CN103172622B (en) | The active isomer of silybin bis-bias succinate | |
| CN102784139A (en) | Pharmaceutical composition for treating diabetes associated with hyperlipemia and preparation method | |
| CN108272767A (en) | A kind of pharmaceutical composition containing BCG polysaccharide nucleic acid | |
| CN101744809B (en) | Combined drug of anethole and fenofibrate drugs | |
| WO1998044005A1 (en) | Pharmacologically active substance | |
| CN1875984A (en) | A medicine for treating dermatosis, venereal diseases, cancer and AIDS and preparation method thereof | |
| CN1234355C (en) | Medicinal composition having anti-inflammation and anti-infection function | |
| CN1465350A (en) | Toad skin preparation and productive process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |